Eugenolol and Glyceryl-Isoeugenol Suppress LPS-Induced INOS Expression by Down-Regulating NF-κB and AP-1 through Inhibition of Mapks and AKT/IκBα Signaling Pathways in Macrophages

• Published in: International journal of immunopathology and pharmacology Vol. 24; no. 2; pp. 345 - 356
• Main Authors: Yeh, J.L., Hsu, J.H., Hong, Y.S., Wu, J.R., Liang, J.C., Wu, B.N., Chen, I.J., Liou, S.F.
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.04.2011
• Subjects: derivatives; transcription factor; lipopolysaccharide; inflammation; mitogen-activated protein kinases
• ISSN: 0394-6320; 2058-7384
• DOI: 10.1177/039463201102400208

Eugenol and isoeugenol, two components of clover oil, have been reported to possess several biomedical properties, such as anti-inflammatory, antimicrobial and antioxidant effects. This study aims to examine the anti-inflammatory effects of eugenol, isoeugenol and four of their derivatives on expression of inducible nitric oxide synthase (iNOS) activated by lipopolysaccharide (LPS) in mouse macrophages (RAW 264.7), and to investigate molecular mechanisms underlying these effects. We found that two derivatives, eugenolol and glyceryl-isoeugenol, had potent inhibitory effects on LPS-induced upregulation of nitrite levels, iNOS protein and iNOS mRNA. In addition, they both suppressed the release of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) induced by LPS. Moreover, they both attenuated the DNA binding of NF-κB and AP-1, phosphorylation of inhibitory κBα (IκBα), and nuclear translocation of p65 protein induced by LPS. Finally, we demonstrated that glyceryl-isoeugenol suppressed the phosphorylation of ERK1/2, JNK and p38 MAPK, whereas eugenolol suppressed the phosphorylation of ERK1/2 and p38 MAPK. Taken together, these results suggest that that eugenolol and glyceryl-isoeugenol suppress LPS-induced iNOS expression by down-regulating NF-κB and AP-1 through inhibition of MAPKs and Akt/IκBα signaling pathways. Thus, this study implies that eugenolol and glyceryl-isoeugenol may provide therapeutic benefits for inflammatory diseases.